Beta Bionics Inc.’s preliminary results for its first full year as a public company offered an early read on developments and market positioning in the insulin pump and patch market, with analysts ...

What the New Price Target Means for Ekso Bionics Holdings Ekso Bionics Holdings is back in focus after a change in the stock's price target, putting fresh attention on how the market is currently ...

Beta Bionics reported Q4 2025 sales growth, but analysts raised concerns about valuation and slower patient starts.

Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities ...

Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 ...